Mulak Agata, Paradowski Leszek
Department of Gastroenterology and Hepatology, Wroclaw Medical University, Poniatowskiego 2, 50-326 Wroclaw, Poland.
World J Gastroenterol. 2006 Mar 14;12(10):1591-6. doi: 10.3748/wjg.v12.i10.1591.
To evaluate the effect of sumatriptan, a selective 5-HT1 agonist, on anorectal function in irritable bowel syndrome (IBS) patients.
Twenty-two IBS patients selected according to the Rome II criteria (F 15, M 7; mean age 29.3+/-6.8, range 22-44 years) were examined. The study was blind, randomized and placebo-controlled with a crossover design. Anorectal manometry and rectal balloon distension test were performed before and after the administration of placebo and sumatriptan.
The administration of sumatriptan caused a significant increase in the resting anal canal pressure from 9.2+/-2.0 kPa to 13.1+/-3.3 kPa (P<0.0001) connected with the increase in the anal sphincter length and high pressure zone. After sumatriptan injection a remarkable increase in the threshold for the first sensation from 27+/-9 mL to 34+/-12 mL (P<0.05) and urge sensation from 61+/-19 mL to 68+/-18 mL (P<0.01) was observed. Sumatriptan did not affect either the volume evoking the rectoanal inhibitory reflex or the results of the straining test.
5-HT1 receptors participate in the regulation of anorectal function. Elucidation of the role of 5-HT1 receptors in the pathophysiological mechanisms of IBS may have some therapeutic implications.
评估选择性5-羟色胺1(5-HT1)激动剂舒马曲坦对肠易激综合征(IBS)患者肛门直肠功能的影响。
选取22例符合罗马II标准的IBS患者(女性15例,男性7例;平均年龄29.3±6.8岁,范围22 - 44岁)进行检查。本研究采用双盲、随机、安慰剂对照的交叉设计。在给予安慰剂和舒马曲坦前后分别进行肛门直肠测压和直肠气囊扩张试验。
给予舒马曲坦后,静息肛管压力从9.2±2.0千帕显著升高至13.1±3.3千帕(P<0.0001),同时肛门括约肌长度和高压区增加。注射舒马曲坦后,首次感觉阈值从27±9毫升显著升高至34±12毫升(P<0.05),便意感觉阈值从61±19毫升升高至68±18毫升(P<0.01)。舒马曲坦对引起直肠肛门抑制反射的容量或用力排便试验结果均无影响。
5-HT1受体参与肛门直肠功能的调节。阐明5-HT1受体在IBS病理生理机制中的作用可能具有一定的治疗意义。